Oncolytic Virotherapy in Breast Cancer

Authors

  • Yuxin Zhu

DOI:

https://doi.org/10.61173/zbwxzd93

Keywords:

Oncolytic virotherapy, breast cancer, cancer therapy

Abstract

Breast cancer has a high incidence and fatality rate, making it a major worldwide health problem. Traditional treatment methods, treatments including chemotherapy, radiation therapy, and surgery, are partially effective in treating advanced breast cancer. Oncolytic viruses are a class of viruses with potential antitumor activity, demonstrating significant promise in cancer therapy through targeted invasion and elimination of tumor cells. In recent years, oncolytic virus therapy and its combination treatments have shown promise in the treatment of breast cancer. This review explores the potential applications of oncolytic viruses, including adenovirus, herpes simplex virus, and vaccinia virus, in breast cancer treatment. The effectiveness, safety, and methods of action of various viruses are covered in the article, as well as the achievements and progress in current research. The objective of this article is to elucidate the advantages of existing oncolytic therapies and inspire the development of novel strategies for treating breast cancer by enhancing understanding and utilization of oncolytic virus therapy. It seeks to harness the potential of new technologies to benefit patients.

References

[1] Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005, 366(9503):2087-2106.

[2] Fisher B, Slack N H, Cavanaugh P J, et al. Postoperative radiotherapy in the treatment of breast cancer: results of the NSABP clinical trial. Annals of surgery. 1970, 172(4):711-732.

[3] Martin O A, Anderson R L. Editorial: Therapy-induced metastasis. Clinical & experimental metastasis. 2018, 35(4):219- 221.

[4] Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. Journal of Cancer. 2017, 8(5):761-773.

[5] Bell J, McFadden G. Viruses for tumor therapy. Cell host & microbe. 2014, 15(3):260-265.

[6] Xia, Z. J., Chang, J. H., Zhang, L., Jiang, W. Q., Guan, Z. Z., Liu, J. W., ... & Zheng, X. (2004). Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of the head and neck or esophagus. Ai Dean&Francis zheng= Aizheng= Chinese journal of cancer, 23(12), 1666-1670.

[7] Hecht J R, Bedford R, Abbruzzese J L, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX- 015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003, 9(2):555-561.

[8] Hartkopf A D, Fehm T, Wallwiener D, et al. Oncolytic virotherapy of breast cancer. Gynecologic oncology. 2011, 123(1):164-171.

[9] Hemminki O, Diaconu I, Cerullo V, et al. Ad3-hTERT- E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Molecular therapy: The Journal of the American Society of Gene Therapy. 2012, 20(9):1821- 1830.

[10] Teplinsky E, Muggia F. Targeting HER2 in ovarian and uterine cancers: challenges and future directions. Gynecologic oncology. 2014, 135(2):364-370.

[11] Liikanen I, Tähtinen S, Guse K, et al. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Molecular cancer therapeutics. 2016, 15(9):2259-69.

[12] Gianni T, Campadelli-Fiume G, Menotti L. Entry of herpes simplex virus mediated by chimeric forms of nectin1 retargeted to endosomes or to lipid rafts occurs through acidic endosomes. Journal of virology. 2004, 78(22):12268-12276.

[13] Russell, W. C. (2009). Adenoviruses: update on structure and function. Journal of General Virology, 90(1), 1-20.

[14] Greig S L. Talimogene Laherparepvec: First Global Approval. Drugs. 2016, 76(1):147-154.

[15] Hu J C, Coffin R S, Davis C J, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colonystimulating factor. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006, 12(22):6737-6747.

[16] Watanabe D, Goshima F, Mori I, et al. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. Journal of Dermatological Science. 2008, 50(3):185-196.

[17] Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Annals of surgical oncology. 2006, 13(8):1078-1084.

[18] Sahin T T, Kasuya H, Nomura N, et al. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenvironment in patients with recurrent breast cancer. Cancer gene therapy. 2012, 19(4):229-237.

[19] Zeng W, Hu P, Wu J, et al. The oncolytic herpes simplex virus vector G47∆ effectively targets breast cancer stem cells. Oncology reports. 2013, 29(3):1108-1114.

[20] Zeng W G, Li J J, Hu P, et al. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer. Oncology reports. 2013, 29(6):2355-61.

[21] Thorne S H, Hwang T H, O‘Gorman W E, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. The Journal of Clinical Investigation. 2007, 117(11):3350-3358.

[22] McCart J A, Ward J M, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer research. 2001, 61(24):8751-8757.

[23] Zeh H J, Downs-Canner S, McCart J A, et al. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Molecular therapy: the journal of the American Society of Gene Therapy. 2015, 23(1):202-214.

[24] Zhang Q, Yu Y A, Wang E, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer research. 2007, 67(20):10038-10046.

[25] Gholami S, Chen C H, Lou E, et al. Vaccinia virus GLV- 1h153, in combination with 131I, shows increased efficiency in treating triple-negative breast cancer. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2014, 28(2):676-82.

[26] Parato K A, Breitbach C J, Le Boeuf F, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Molecular therapy: the journal of the American Society of Gene Therapy. 2012, 20(4):749-758.

[27] Deng L, Fan J, Ding Y, et al. Target Therapy With Vaccinia Virus Harboring IL-24 For Human Breast Cancer. Journal of Cancer. 2020, 11(5):1017-1026.

[28] Kochneva G, Sivolobova G, Tkacheva A, et al. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy. Oncotarget. 2016, 7(45):74171-74188.

[29] Heery C R, Ibrahim N K, Arlen P M, et al. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA oncology. 2015, 1(8):1087- 1095.

[30] Hata Y, Etoh T, Inomata M,et al. Efficacy of oncolytic reovirus against human breast cancer cells. Oncology reports. 2008, 19(6):1395-1398.

[31] Marcato P, Dean C A, Giacomantonio C A, Lee PW. Oncolytic reovirus effectively targets breast cancer stem cells. Molecular therapy: the journal of the American Society of Gene Therapy. 2009, 17(6):972-979.

[32] Rodríguez Stewart R M, Berry J T L, Berger A K, et al. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors. Journal of virology. 2019, 93(23):e01411-e01419.

[33] Iankov I D, Msaouel P, Allen C, et al. Demonstration of antitumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast cancer research and treatment. 2010, 122(3):745-754.

Downloads

Published

2024-06-06

Issue

Vol. 2 No. 3 (2024): Volume 2, Issue 3

Section

Articles

License

Copyright (c) 2024 by the authors.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.